Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-23
2007-01-23
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C530S300000, C530S350000
Reexamination Certificate
active
09020393
ABSTRACT:
Compounds modulating CD59 mediated complement activity, compositions including these compounds, and methods of making and using the compounds are disclosed, which are based on the identification of the hu CD59 amino acid residues which serve as the binding site for CD59-C9 interactions. These residues correspond to amino acid residues 42–58, and bind to the region of C9 corresponding to human 334–418, more specifically, between amino acid residues 359 and 384. Compounds can be derived using this basic amino acid sequence and corresponding three dimensional structure within the protein using any of several techniques known to those skilled in the art, including rational drug design using computer data bases and modeling of peptide/protein-ligand binding, antibodies and anti-idiotypic antibodies generated to the proteins or peptides containing this peptide sequence, and modified peptides. Those compounds imitating the structure and/or function of the peptide region are referred to herein as “peptidomimetics”, and include small molecules which present the surface exposed side chains in these amino acids in the same relative positions, compounds identified by combinatorial chemistry techniques which bind to the active portions of human C9, as well as modified peptides. The compounds can be used to inhibit complement by binding to C9 analogously to CD59, or to maintain complement inhibition, by blocking CD59 binding to C9. The compounds can be administered locally or systemically in any suitable carrier in an amount effective to either inhibit complement or block the inhibition of complement, in a patient in need of treatment thereof.
REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4447415 (1984-05-01), Rock
patent: 4629784 (1986-12-01), Stammer
patent: 4695460 (1987-09-01), Holme
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4916219 (1990-04-01), Linhardt et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5135916 (1992-08-01), Sims et al.
patent: 5550108 (1996-08-01), Sims et al.
patent: 5573940 (1996-11-01), Sims et al.
patent: 5612895 (1997-03-01), Balaji et al.
patent: 5624837 (1997-04-01), Fodor et al.
patent: 5843884 (1998-12-01), Sims
patent: 0351313 (1989-07-01), None
patent: 0394035 (1990-04-01), None
patent: WO 93/01286 (1993-01-01), None
patent: WO 95/23856 (1995-09-01), None
patent: WO 97/17987 (1997-05-01), None
Agrawal, et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus,”Proc. Natl. Acad. Sci. USA85(19):7079-7083 (1988).
Allen, et al., “The Cambridge Crystallographic Data Centre: Computer-Based Search, Retrieval, Analysis and Display of Information,”Acta Cryst. B35:2331-2339 (1979).
Amies, “The Use of Topically Formed Calcium Alginate as a Depot Substance in Active Immunisation”J. Path. Bact.77:435-442 (1959).
Ando, et al., “The Secretory Release Reaction Initiated by Complement Proteins C5b-9 Occurs Without Platelet Aggregation Through Glycoprotein II-b-IIIa,”Blood73(2):462-467 (1989).
Ando, et al., “Complement Proteins C5b-9 Initiate Secretion of Platelet Storage Granules without Increased Binding of Fibrinogen or von Willebrand Factor to Newly Expressed Cell Surface GPIIb-IIIa,”J. Biol. Chem.263(24):11907-11914 (1988).
Archakov, et al.,Vestn. Ross. Akad. Med. Nauk.1:60-63 (1996).
Askew, et al., “Molecular recognition with Convergent Functional Groups”J. Am. Chem. Soc., 111:1082-1090 (1989).
Bevers, et al., al. “Defective Ca2+−Induced microvesiculation and deficient Expression of Procoagulant Activity in Erythrocytes From a patient with a Bleeding Disorder” A Study of the Red Blood Cells of Scott SyndromeBlood79(2): 380-388 (1992).
Blaas, et al., Paroxysmal Nocturnal HemoglobinuriaJ. Immunology140:3045-3051 (1988).
Bodian, et al., al., “Mutational Analysis of the Active Site and Antibody Epitopes of the Complement-inhibitory Glycoprotein CD59,”J. Exp. Med.185(3):507-516 (1997).
Braga, et al. “A Monoclonal Antibody to the Galactose-Specific Adhesin Abrogates the resistance ofE. histolyticato Lysis by Human Complement C5b-9”XIV International Complement WorkshopCambridge, U.K. (1991).
Brint, “Upperbound procedures for the identification of similar three-dimensional chemical structures,”J. Comput.-Aided Mol. Design2:311-310 (1988).
Burgess, et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-bind Activities by Site-directed Mutagenesis of a Single Lysine Residue,”J. Cell Biology111:2129-2138 (1990).
Chang, et al. “Identity of a Peptide Domain of Human C9 That Is Bound by the Cell-surface Complement Inhibitor, CD59,”J. Biol. Chem. 269(42):26424-26430 (1994).
Clackson, et al., “Making antibody fragments using phage display libraries,”Nature352:624-688 (1991).
Cooper, et al., “A novel approach to molecular similarity,”J. Comput.-Aided Mol. Design3:253-259 (1989).
Cross, “Glycolipid Anchoring of Plasma Membrane Proteins”Annu. Rev. Cell Biol. 6:1-39 (1990).
Daugherty, et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins,”Nucl. Acids Res. 19(9):2471-2476 (1991).
Davies, et al., “CD59, An LY-6-Like Protein Expressed in Human Lymphoid Cells, Regulates the Action of the Complement Membrane Attack Complex on Homologous Cells,”J. Exp. Med. 170(3):637-654 (1989).
Davies, et al. “Membrane Defense against Complement Lysis: The Structure and Biological Properties of CD59,”Immunol. Res. 12(3):258-275(1993).
Dupuis, et al., “Mutations in the Putative Lipid-Interaction Domain of Complement C9 Result in Defective Secretion of the Functional Protein,”Mol. Immunol. 30(1):95-100 (1993).
Fletcher, et al., “Sequence-specific1H-NMR assignments and folding topology of human CD59,”Protein Sci. 2:2015-2027 (1993).
Fletcher, et al., “Structure of soluble, glycosylated form of the human complement regulatory protein CD59,”Structure2:185-199 (1994).
Gerber, et al., “Phosphatidylinositol Glycan (PI-G) Anchored Membrane Proteins,”J. Biol. Chem. 267(17):12168-12173 (1992).
Ghoshal, et al., “Computer Aids in Drug Design—Highlights”Pol. J. Pharmacol. 48(4): 359-377 (1996).
Gilbert, et al. “Platelet-derived Microparticles Express High Affinity Receptors for Factor VIII”J. Biol. Chem266(8): 1-8 (1991).
Gregoriadis, “Liposomes,” inDrug Carriers in Biology and Medicine, Chap. 14, pp. 287-341 (Academic Press, 1979).
Groux, et al., “A 19-kDa Human Erythrocyte Molecule H19 is Involved in Rosettes, Present on Nucleated Cells, and Required for T Cell Activation,”J. Immunology142(9):3013-3020 (1989).
Hahn, et al. “Overlapping But Nonidentical Binding Sites on CD2 for CD58 and a second Ligand CD59”Science256: 1805-1807 (1992).
Hamilton, et al. “The Terminal Complement Proteins C5b-9 Augment Binding of High Density Lipoprotein and its Apolipoproteins A-I and A-Ii to Human Endothelial Cells”J. Clin. Invest88: 1833-1840 (1991).
Hamilton, et al., “Complement Proteins C5b-9 Induce Vesiculation of the Endothelial Plasma Membrane and Expose Catalytic Surface for Assembly of the Prothrombinase Enzyme Complex”J. Bio. Chem., 265:3809-3814 (1990).
Hamilton, et al., “Regulatory Control of the Terminal Complement Proteins at the Surface of Human Endothelial Cells: Neutralization of a C5b-9 Inhibitor by Antibody to CD59,”Blood76(12):257
Fulbright & Jaworski
Gambel Phillip
Oklahoma Medical Research Foundation
LandOfFree
Compositions and methods to inhibit formation of the C5b-9... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods to inhibit formation of the C5b-9..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods to inhibit formation of the C5b-9... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747968